Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G6CF
|
|||
| Drug Name |
B-701
|
|||
| Synonyms |
VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester
Click to Show/Hide
|
|||
| Indication | Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 2 | [1], [2] | |
| Urothelial carcinoma [ICD-11: 2C92.0] | Phase 1 | [2] | ||
| Company |
BioClin Therapeutics San Ramon, CA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H22Cl3N2O3P
|
|||
| Canonical SMILES |
C(CNP(=O)(N(CCCl)CCCl)OCCCCl)CO
|
|||
| InChI |
1S/C10H22Cl3N2O3P/c11-3-1-10-18-19(17,14-6-2-9-16)15(7-4-12)8-5-13/h16H,1-10H2,(H,14,17)
|
|||
| InChIKey |
VKRFJPYJBOIVPD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 78218-88-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fibroblast growth factor receptor 3 (FGFR3) | Target Info | Antagonist | [2] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Signaling pathways regulating pluripotency of stem cells | ||||
| Regulation of actin cytoskeleton | ||||
| Pathways in cancer | ||||
| MicroRNAs in cancer | ||||
| Bladder cancer | ||||
| Central carbon metabolism in cancer | ||||
| Panther Pathway | FGF signaling pathway | |||
| Reactome | FGFR3 mutant receptor activation | |||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Endochondral Ossification | ||||
| Bladder Cancer | ||||
| Neural Crest Differentiation | ||||
| Signaling by FGFR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.